June 28, 2021

CMRSurgicalVersius400x275CMR Surgical has announced it raised $600 million (£425 million) in a Series D financing round. The round was co-led by SoftBank Vision Fund 2 and Ally Bridge Group, with the goal of making keyhole surgery accessible to more people worldwide. The funding will be used to increase the global commercialization of CMR’s Versius next-generation surgical robotic system and further develop its digital ecosystem, the company said.

CMR said it works with surgeons and hospitals to make robotic keyhole surgery universally accessible and affordable. The size, portability and versatility of Versius has made it popular with hospitals and surgeons around the world, the company added. The system has been deployed in multiple geographies worldwide, including Europe, Australia, India, and the Middle East (the system is not yet approved for use in the U.S.).

Versius  can fit into almost any operating room setup, integrating into existing workflows to increase the likelihood of robotic minimal access surgery. Biomimicking the human arm, Versius gives surgeons the choice of optimized port placement alongside the dexterity and accuracy of small fully wristed instruments, CMR said. With 3D HD vision, instrument control and a choice of ergonomic working positions, the open surgeon console aims to reduce stress and fatigue, allowing for clear communication with the surgical team. In addition, Versius captures data through its wider digital ecosystem, supporting a surgeon’s continuous learning through the Versius Connect app, Versius Trainer, and CMR clinical registry.

“This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals,” said Per Vegard Nerseth, CEO of CMR. “This major injection of capital that now values us at $3 billion not only reflects the level of interest we have seen in our product, but also the scale of the business, and will enable significant technology developments and global expansion.”

Other investors participating in this round include RPMI Railpen, Tencent and Chimera, as well as existing investors LGT and its affiliate impact investing platform Lightrock, Watrium, Cambridge Innovation Capital, PFM Health Sciences and GE Healthcare.

“As life science-dedicated specialists and active investors in surgical robotics, we believe the user-friendliness and cost-effectiveness of the Versius system allows a meaningfully differentiated robotic experience that democratizes robotic surgery both procedurally and geographically,” said Charles Chon, partner and head of MedTech at the Ally Bridge Group. “We are proud to support CMR as a hallmark of U.K. innovation and a solution for all surgeons and their patients.”

More details on CMR Surgical and its Versius system can be found here.